secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001725160-24-000007
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones
--------------------------------------------------------------------------------

- Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.
- Zentalis receives $35M upfront in cash and Immunome common stock; eligible for up to $275M milestones plus mid-to-high single-digit royalties.
- Immunome plans to submit IND for ZPC-21 in 1Q 2025.
- Zentalis to focus resources on advancing azenosertib (WEE1 inhibitor) in multiple clinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/0001725160-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/zntl-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer